Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma
出版年份 2021 全文链接
标题
Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-11-18
DOI
10.1038/s41598-021-00944-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer
- (2020) HYUN LEE et al. ANTICANCER RESEARCH
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
- (2020) Emily S. Reisenbichler et al. MODERN PATHOLOGY
- Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
- (2020) Jin Sun Lee et al. Cancers
- RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens
- (2020) Maxim Sorokin et al. Biomedicines
- PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
- (2019) Elisabeth Specht Stovgaard et al. BREAST CANCER RESEARCH AND TREATMENT
- PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2019) Qi Du et al. Clinical Breast Cancer
- Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy
- (2019) Anne-Sophie Hamy et al. CLINICAL CANCER RESEARCH
- Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
- (2019) Federica Miglietta et al. ONCOLOGIST
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
- (2018) Waqar Haque et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
- (2018) Alice Lee et al. CANCER TREATMENT REVIEWS
- Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
- (2018) Yunxuan Wang et al. Journal of Breast Cancer
- Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
- (2018) Vasiliki Pelekanou et al. MOLECULAR CANCER THERAPEUTICS
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exosome-mediated breast cancer chemoresistance via miR-155 transfer
- (2018) Juliana Carvalho Santos et al. Scientific Reports
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
- (2017) Bruna Cerbelli et al. Biomed Research International
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives
- (2016) Catherine E Steding Future Oncology
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- (2016) Carsten Denkert et al. MODERN PATHOLOGY
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Biomarker assessment and molecular testing for prognostication in breast cancer
- (2015) Zuzana Kos et al. HISTOPATHOLOGY
- Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
- (2015) Elena Provenzano et al. MODERN PATHOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
- (2008) S. Ladoire et al. CLINICAL CANCER RESEARCH
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- (2008) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started